also relatively less sensitive disease

French translation: see explanation of English

Advertisement

Login or register (free and only takes a few minutes) to participate in this question.

You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.

12:51 Oct 27, 2007

English to French translations [PRO]Medical - Medical: Pharmaceuticals / genetics

English term or phrase:also relatively less sensitive disease

Deux produits sont actifs dans la LMC : nilotinib et imatinib. Le nilotinib a la même efficacité que les patients LMC, au préalable, se soient montrés ou non résistants/intolérants à l'imatinib.
Ci-après le texte qui donne la logique de cette similiraté des résultats, mais que je ne comprends pas :
"The estimated percent of patients who achieved a major cytogenetic response and who did not discontinue nilotinib due to progression or death for at least 6 months after achievement of response was 96% (Figure 2). Similar rates of major cytogenetic response were observed in resistant- and intolerant- patients. This is likely due to the rigorous definition of imatinib intolerance, which excluded imatinib-intolerant patients who had achieved a prior major cytogenetic response (thus the imatinib-intolerant patients had -also relatively less sensitive disease-)."

Explanation:Imatinib intolerance was defined in such a way that patients who had achieved a major cytogenetic response previously could not be classified as imatinib-intolerant. The effect is that, by definition, the imatinib-intolerant patients all had pathologies that were probably less likely to respond to treatment (with nilotinib), since those with sensitive disease - "good responders" - were excluded.

>> the potential for response was similar in both imatinib-intolerant and imatinib-resistant groups.

Explanation:Imatinib intolerance was defined in such a way that patients who had achieved a major cytogenetic response previously could not be classified as imatinib-intolerant. The effect is that, by definition, the imatinib-intolerant patients all had pathologies that were probably less likely to respond to treatment (with nilotinib), since those with sensitive disease - "good responders" - were excluded.

>> the potential for response was similar in both imatinib-intolerant and imatinib-resistant groups.